CAST as a Tumor-Specific Suppressor in Colorectal Cancer: Discovery Through Integrative Analysis of Unannotated Isoforms, Proteomics, and Epigenetic Regulation
- 1Islamic Azad University, Shahriar Branch
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, yet the molecular mechanisms driving tumor initiation and progression are incompletely understood. Here, we integrate single-cell long-read sequencing, proteomics, and DNA methylation data to identify tumor-specific targets from unannotated isoforms in CRC. Analysis of 29,429 isoforms across 3,262 single cells revealed 3,338 novel isoforms, comprising 2,779 Novel In Catalog (NIC) and 559 Novel Not in Catalog (NNC). Cross-referencing with 68 normal tissues from GTEx identified 3 tumor-specific candidates absent from normal colon. Among these, CAST (Calpastatin) emerged as a tumor-specific suppressor, with a 63.1-fold higher expression in tumor (2.62) versus normal colon (0.03). CAST protein was confirmed in 100 tumor samples by mass spectrometry (mean expression: 0.22). Mutational analysis of 100 CRC samples revealed 8 deleterious mutations, including 2 nonsense, 2 splice-site, 2 missense, 1 frameshift, and 1 in-frame variant, consistent with a tumor-suppressor role. Promoter methylation analysis of 393 tumor samples showed that 89.3% (351/393) were hypomethylated ({beta} < 0.1), whereas only 1.5% (6/393) were hypermethylated ({beta} > 0.3), indicating demethylation-mediated reactivation. Furthermore, CAST expression was negatively correlated with promoter methylation and regulated by the miR-200 family (miR-200c: 13.48, miR-141: 10.13, miR-429: 8.09). Our findings establish CAST as a tumor-specific suppressor in CRC and provide a generalizable framework for discovering therapeutic targets from unannotated isoforms.
Related
- Integrative Multi-Database Bioinformatics Characterization of FANCE in Hepatocellular Carcinoma: Prognostic, Epigenetic, Immune, and ncRNA Associations
- Longitudinal Drain-Fluid Proteomics Reveals Procedure-Specific Signatures of Postoperative Leakage after Pancreatic and Colorectal Surgery
- p38α MAPK integrates opposing oncogenic APC/β-catenin/TCF and GUCY2C tumor-suppressor axes in colorectal cancer
- Epigenetic Exposure Signatures Distinguish Early-Onset from Later-Onset Colorectal Cancer in a Racially Diverse US Cohort: Findings from the Disparities and Cancer Epidemiology (DANCE) Study
- Integrative Proteomics Reveals That Ejiao Alleviates Premature Ovarian Insufficiency and Restores Bone Metabolism in Mice
BibTeX
@misc{ebadi2026cast,
title = {{CAST as a Tumor-Specific Suppressor in Colorectal Cancer: Discovery Through Integrative Analysis of Unannotated Isoforms, Proteomics, and Epigenetic Regulation}},
author = {A. Ebadi and M. Hashemi},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.17.26363321},
url = {https://www.medrxiv.org/content/10.64898/2026.09.17.26363321v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - CAST as a Tumor-Specific Suppressor in Colorectal Cancer: Discovery Through Integrative Analysis of Unannotated Isoforms, Proteomics, and Epigenetic Regulation
AU - A. Ebadi
AU - M. Hashemi
PY - 2026
DA - 2026/09/17
PB - medRxiv
DO - 10.64898/2026.09.17.26363321
UR - https://www.medrxiv.org/content/10.64898/2026.09.17.26363321v1
AB - Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, yet the molecular mechanisms driving tumor initiation and progression are incompletely understood. Here, we integrate single-cell long-read sequencing, proteomics, and DNA methylation data to identify tumor-specific targets from unannotated isoforms in CRC. Analysis of 29,429 isoforms across 3,262 single cells revealed 3,338 novel isoforms, comprising 2,779 Novel In Catalog (NIC) and 559 Novel Not in Catalog (NNC). Cross-referencing with 68 normal tissues from GTEx identified 3 tumor-specific candidates absent from normal colon. Among these, CAST (Calpastatin) emerged as a tumor-specific suppressor, with a 63.1-fold higher expression in tumor (2.62) versus normal colon (0.03). CAST protein was confirmed in 100 tumor samples by mass spectrometry (mean expression: 0.22). Mutational analysis of 100 CRC samples revealed 8 deleterious mutations, including 2 nonsense, 2 splice-site, 2 missense, 1 frameshift, and 1 in-frame variant, consistent with a tumor-suppressor role. Promoter methylation analysis of 393 tumor samples showed that 89.3% (351/393) were hypomethylated ({beta} < 0.1), whereas only 1.5% (6/393) were hypermethylated ({beta} > 0.3), indicating demethylation-mediated reactivation. Furthermore, CAST expression was negatively correlated with promoter methylation and regulated by the miR-200 family (miR-200c: 13.48, miR-141: 10.13, miR-429: 8.09). Our findings establish CAST as a tumor-specific suppressor in CRC and provide a generalizable framework for discovering therapeutic targets from unannotated isoforms.
ER -